Crinetics Pharmaceuticals Inc

Strip the year back and a single month does the heavy lifting: November, up in 7 of 8 Novembers while the other eleven tend to blur together.

Its average (+7.6%) and median (+5.8%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even November ranges by 10.8% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: November has cleared the S&P 500 by +5.3 points above the index. That consistency sets it apart from the field, where the average stock manages November only about 62% of the time.

The strength clusters rather than stands alone — October–December forms a firm stretch that carries much of the year. The weaker half of the year is plainer: September is the year's low point, though even there the stock has stayed positive on average (+8.6%), a sign every month leans up, and the edge isn't year-round — the stock has trailed the S&P 500 in January, March, and July. Its roughest month on record was a −33.3% January in 2022 — a reminder of how hard even a seasonal name can fall.

The pattern has softened of late, November's last five years slipping below its longer-run record.

The takeaway is less about when to buy than what to expect: November aside, the stock's months offer little reliable tilt. With a short 8-year record and returns that swing hard year to year, the signal is best held loosely.